

ONCOPOOL is up to date, based on data direct from Units rather than from tumour registries, data is much more complete than SEER, there is greater accuracy in survival prediction and 10 yr survival figures rather than 5 yr are given.

ONCOPOOL should be regarded as the standard European dataset for primary breast cancer.

O-10 Changing pattern of the detection of loco-regional relapse in breast cancer: The Edinburgh Experience

D.A. Montgomery*, K. Krupa, W.J.L. Jack, G.R. Kerr, I.H. Kunkler, J. Thomas, J.M. Dixon. *Western General Hospital, Edinburgh, UK*

Guidelines exist for follow-up of breast cancer patients. Follow-up is concentrated on the first three to five years, with either reduced frequency of visits or discharge after this. Guidelines recommend mammography; no evidence exists to inform frequency. We analyse treatable relapses in our unit from 1312 patients with early stage breast cancer treated by breast conserving surgery (BCS) and post-operative radiotherapy between 1991 and 1998 to assess appropriateness of the guidelines. 110 treatable relapses were analysed. Treatable relapse developed at 1–1.5% per year throughout follow-up. 48 relapses were in ipsilateral breast, 25 ipsilateral axilla, 35 contralateral breast and 2 both breasts simultaneously. 37 relapses (33.5%) were symptomatic, 56 (51%) mammographically detected, 15 (13.5%) clinically detected, 2 (2%) diagnosed incidentally. Mammography detected 5.37 relapses per 1000 mammograms. Patients with symptomatic or mammographically detected ipsilateral breast relapse had significantly longer survival from original diagnosis ($p=0.0002$) and from recurrence ($p=0.0014$) compared with clinically detected relapse. Treatable relapse occurs at a constant rate to at least ten years. Clinical examination detects a minority (13.5%). Relapse diagnosed clinically is associated with poorer outcome. Long-term follow-up based on regular mammography is warranted for all patients treated by BCS.

O-11 Radiotherapy and/or tamoxifen after conserving surgery for breast cancers of excellent prognosis: BASO II TRIAL

R.W. Blamey, U. Chetty*, T. Bates, S. Duffy, I.O. Ellis, D. George, E. Mallon, M.J. Mitchell, D.A.L. Morgan, R.D. Macmillan, J. Patnick, S. Pinder, on behalf of the BASO (British Association of Surgical Oncology) II Trialists, Royal College of Surgeons, London

The BASO II trial was of intact breast irradiation (RT) versus No RT and/or Tamoxifen versus No Tamoxifen following breast conserving surgery, in patients with primary invasive breast cancers of excellent prognosis.

Primary objective: To determine the rates of local recurrence (LR) for the various regimes, defined as further cancer in the tissue or skin of the treated breast.

Secondary objectives: breast cancer specific survival rates; contralateral breast cancer rates.

Method: 2x2 design with entry allowed to one or other comparison as well as to both. Life table analysis (Log Rank) according to randomisation and to treatment received.

Results: Median FU 122 months. 10 year breast cancer specific survival (Life table) 96%.

The results of the randomisation (intention to treat) show that operative surgery without an additional treatment is significantly worse in terms of LR than treatment with either therapy and particularly so when treatment excluded both therapies. There was no significant

difference in LR between the addition of RT alone and the use of Tamoxifen alone

Analysis by treatment received (Table) showed the average rate of local recurrence to 10 years of follow-up is 1.6% per annum in the group receiving neither therapy against 0.1% per annum in those receiving both; recurrence rates are 0.5% per annum in those receiving only Tamoxifen and only RT.

Treatment received	No LR n	LR n	LR%	LR rate p.a (%)
No RT no TAM	146	29	16.6	1.6
RT no TAM	172	10	5.5	0.5
TAM no RT	401	20	4.8	0.5
RT + TAM	376	4	1.1	0.1

Conclusions: Even in this group of early tumours of least aggression, wide local excision alone has a rate of LR around 1.5% PA. This rate is significantly reduced by receipt of either RT or Tamoxifen. Recurrence rate is very low at around 0.1% PA following receipt of both adjuvant therapies.

O-12 Radiation therapy after breast-conserving surgery: randomised trial in patients with low risk of recurrence

K.-J. Winzer*, R. Sauer, W. Sauerbrei, E. Schnellei, W. Jaeger, M. Braun, J. Dunst, T. Liersch, M. Zedelius, K. Brunnert, H. Guski, C. Schmoor, M. Schumacher, for the German Breast Cancer Study Group (GBSB)

To study the role of radiotherapy and Tamoxifen after breast-conserving surgery (BCS) in patients with a favourable prognosis, a clinical trial was initiated by the German Breast Cancer Study Group. Between 1991 and 1998, 361 patients (pT1pN0M0, aged 45 – 75 years, receptor positive, grade I-II) were randomised to radiotherapy (yes/no) and Tamoxifen for 2 years (yes/no) in a 2x2 factorial design; the exclusion of seven centres (14 patients) left 347 patients in the analysis.

After a median follow-up of 5.9 years, 77 events concerning event-free survival were observed. Mainly due to local recurrences, the event rate was about three times higher in the group with BCS only than in the other three groups. No difference could be established between the four treatments groups for distant disease-free survival rates. It was concluded that even in patients with a favourable prognosis, the avoidance of radiotherapy and Tamoxifen after BCS increased the rate of local recurrences substantially.

The results of a median follow-up of nine years will be presented.

O-13 Differential expression of ER and Ki67 in normal breast tissue and proliferating breast disease: further support of the progenitor cell concept?

W. Boecker*, C. Löchnert*, E. Korsching*. *University of Munster, Germany*

In 2002/2003 we proposed a progenitor cell model of normal human breast epithelium, in which Ck5/14-positive cells give rise to both the glandular (Ck8/18+) and myoepithelial cell lineages. We further suggested a model of how proliferative lesions and carcinoma develop.

Aim: To test these hypotheses in resting breast epithelium (n=6), usual ductal hyperplasia (UDH) (n=4), FEA (n=3), ADH (n=6), DCIS (n=6) and LN (n=4) using an in-situ double immunostaining method (for example ER vs. Ck8/18, ER vs. Ck5/6, ER vs. ki67, ki67 vs. Ck8/18